Cefprozil for Oral Suspension USP, 250mg/5mL, packaged as a) 50 mL (when mixed) bottles (NDC 6818...

FDA Recall #D-0332-2021 — Class II — March 26, 2021

Recall #D-0332-2021 Date: March 26, 2021 Classification: Class II Status: Terminated

Product Description

Cefprozil for Oral Suspension USP, 250mg/5mL, packaged as a) 50 mL (when mixed) bottles (NDC 68180-402-01); b) 75 mL (when mixed) bottles (NDC 68180-402-02); and c) 100 mL (when mixed) bottles (NDC 68180-402-03); Rx only, Manufactured for: Lupin Pharmaceutical, Inc., Baltimore, MD 21202; Manufactured by: Lupin Limited, Mandideep 462 046, India.

Reason for Recall

Superpotent Drug

Recalling Firm

Lupin Pharmaceuticals Inc. — Baltimore, MD

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

a) 6,816 bottles; b) 3,960 bottles and c) 7,038 bottles

Distribution

Nationwide in the USA and Puerto Rico

Code Information

Lot Numbers: a) F801122, exp. date June 2021; b) F801123, exp. date June 2021; c) F801124, exp. date June 2021

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated